125 related articles for article (PubMed ID: 22758220)
1. Acute myeloid leukaemia with abnormal eosinophil precursors without inversion 16.
Rashidi A; Roullet MR
Br J Haematol; 2012 Sep; 158(5):561. PubMed ID: 22758220
[No Abstract] [Full Text] [Related]
2. Marked hypereosinophilia and rash as initial presentation of acute myeloid leukemia with t(8;21).
Ong SY; Ho LP; Yeo PM; Ng HJ; Ang AL
Int J Hematol; 2017 Aug; 106(2):149-150. PubMed ID: 28390036
[No Abstract] [Full Text] [Related]
3. Bullous leukaemia cutis.
Kikuchi N; Yamamoto T
Eur J Dermatol; 2012; 22(1):148-9. PubMed ID: 22237386
[No Abstract] [Full Text] [Related]
4. Idarubicin in combination with etoposide and cytarabine in adult acute non-lymphoblastic leukaemia (ANLL).
Carella AM; Pungolino E; Piatti G; Giordano D; Cerri R; Risso M; Nati S
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():50-1. PubMed ID: 2713562
[No Abstract] [Full Text] [Related]
5. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Lambertenghi-Deliliers G; Annaloro C; Cortelezzi A; Cortellaro M; Della Volpe A; Maiolo AT; Mozzana R; Pogliani E; Pozzoli E; Polli EE
Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
[No Abstract] [Full Text] [Related]
6. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
[No Abstract] [Full Text] [Related]
7. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
[No Abstract] [Full Text] [Related]
8. Systemic mastocytosis associated with acute myeloid leukaemia.
Fong C; Tong M
Pathology; 2010; 42(5):485-7. PubMed ID: 20632831
[No Abstract] [Full Text] [Related]
9. Marked bone marrow eosinophilia at the time of relapse of acute myeloblastic leukaemia in association with the appearance of translocation t(12;20)(q24;q11).
Partridge F; Richardson W; Kearns P; Wilcox R; Majumdar G
Leuk Lymphoma; 1996 Jun; 22(1-2):181-2. PubMed ID: 8724547
[TBL] [Abstract][Full Text] [Related]
10. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia.
La Starza R; Trubia M; Testoni N; Ottaviani E; Belloni E; Crescenzi B; Martelli M; Flandrin G; Pelicci PG; Mecucci C
Haematologica; 2002 Aug; 87(8):789-94. PubMed ID: 12161353
[TBL] [Abstract][Full Text] [Related]
11. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
[No Abstract] [Full Text] [Related]
12. Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: case report and review of literature.
Zhang XH; Zhang R; Li Y
Leuk Res; 2010 Jul; 34(7):958-61. PubMed ID: 20116851
[TBL] [Abstract][Full Text] [Related]
13. Proliferation and maturation effects of in-vivo granulocyte-macrophage colony stimulating factor in acute non-lymphocytic leukaemia.
Damiani D; Michieli M; Revignas MG; Russo D; Fanin R; Michelutti A; Mallardi F; Baccarani M
Haematologica; 1992; 77(1):25-9. PubMed ID: 1398278
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin in acute leukemia: results of US trials.
Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
[No Abstract] [Full Text] [Related]
15. [Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
Helg C; Chapuis B; Grob JP; Pugin P
Schweiz Med Wochenschr; 1990 Apr; 120(15):548-52. PubMed ID: 2336558
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
17. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Petti MC; Mandelli F
Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
[No Abstract] [Full Text] [Related]
18. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
19. Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Wilda M; Perez AV; Bruch J; Woessmann W; Metzler M; Fuchs U; Borkhardt A
Genes Chromosomes Cancer; 2005 Aug; 43(4):424-6. PubMed ID: 15852479
[No Abstract] [Full Text] [Related]
20. Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2).
Corral Mdel P; Villa O; Alfaro EM; Alonso CN; Baro C; Felice MS; Rossi J; Solé F; Gallego MS
Pediatr Blood Cancer; 2008 Mar; 50(3):651-4. PubMed ID: 17405156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
